Anavex Reports That New Data Confirms Calcium Target Over-Expression May Be Involved in Causing Alzheimer’s Disease

Same Target Regulated Through Sigma-1 Receptor   New York — May 22, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, welcomes new data published in the current…

Anavex Provides Business Update Including Clinical Trial Plans for ANAVEX PLUS in Alzheimer’s Disease

Reports Fiscal Second Quarter Financial Results New York, NY — May 15, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, today provided a business update including…

Anavex Appoints Senior Healthcare and Pharmaceutical Executives to Board of Directors

New York, NY — May 8, 2014 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, today announced the appointment of Bernd Metzner, PhD and Elliot Favus, MD…